Communiqués Exelixis, Inc.

Actions

EXEL

US30161Q1040

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/06/2026			Pré-ouverture 15:28:35
54,77 ^USD	+2,89%		53,97	-1,46%

22/06	Exelixis fait le point sur l'essai de phase 3 STELLAR-303 évaluant le zanzalintinib en association avec un inhibiteur de point de contrôle immunitaire chez des patients atteints de cancer colorectal métastatique	CI
09/06	Transcript : Exelixis, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 10:40 AM

Communiqués

22/06	Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer	BU
30/05	Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026	BU
27/05	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June	BU
21/05	Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types	BU
19/05	Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer	BU
11/05	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May 2026	AQ
07/05	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May	BU
06/05	Exelixis : Quarterly Report for Quarter Ending April 3, 2026 (Form 10-Q)	PU
06/05	Exelixis : 260505 Exelixis Q1 2026 Earnings Slides With Appendix	PU
05/05	Exelixis: Q1 Earnings Snapshot	AQ
05/05	Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update	BU
21/04	Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026	BU
24/02	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March	BU
10/02	Exelixis : 260210 Exelixis Q4 & FY25 Earnings Presentation With Appendix	PU
10/02	Exelixis : Annual Report for Fiscal Year Ending January 2, 2025 (Form 10-K)	PU
10/02	Exelixis: Q4 Earnings Snapshot	AQ
10/02	Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update	BU
02/02	Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer	BU
27/01	Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026	BU
13/01	Exelixis : 260112 Exelixis JP Morgan 2026 Presentation	PU
11/01	Exelixis : Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026	PU
11/01	Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026	BU
07/01	Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer	BU
06/01	Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026	BU
10/12	Exelixis : 251210 Exelixis 2025 R&D Day Presentation	PU